DxMedical Cloud™
Technology for overwhelmingly high-speed detection from all over the world.
We use our unique algorithm to deliver the latest technology and product information from around the world in real time.
Explore the future of healthcare with carefully selected information.
Explore the future of healthcare with carefully selected information.
Login
How We Help You To Empower Your Business
POINT 1.
Quickly Deliver Technical Information
We deliver what you seek quickly and in a short time from technical information from all over the world
POINT 2.
Briefly to the Point
A wealth of detailed features makes it easy to understand the main points
POINT 3.
Help with Growth Strategies
The report is also packed with analytical information from the perspective of growth and long-term strategies for business use
Catch Up on the Latest Information
from Around the World
from Around the World
In today's world, where the world is networked by advances in information technology and numerous technologies are evolving at an astonishing speed, it is extremely difficult to manually collect and manage the vast amount of information from all over the world.
DxMedical Cloud™ collects and analyzes professional information from around the world and uses proprietary algorithms to quickly and accurately deliver the information you seek and the best information for you.
search
Quick search in Japanese
You can quickly search for information published in various languages around the world in Japanese. Get the information you need from the vast amount of information available worldwide without having to worry about language barriers.
emergency
Recommendations for You
DxMedical Cloud's proprietary algorithms predict the best information based on your interests and preferences and deliver it to you daily. Stay one step ahead of the curve without the hassle of searching, maximizing your daily information gathering.
Fuzzy Search
In addition to word matching, the search by similar and related keywords delivers news that is often missed due to paraphrasing and shaky spelling.
Japanese Localization
By providing titles and summaries of information from around the world in Japanese, it streamlines the process of “finding” the information you want from search results.
Academic Search
For researchers and professionals, you can search and browse more specialized information, such as articles submitted to journals by universities and research institutes.
More features to enhance your team's productivity
Bookmark
Instantly save and manage information that you like or want to look at later because you don't have time, with the bookmark function. You can access the information you need without hassle, saving you a great deal of time and effort.
Note Editor
Simple and intuitive operation allows you to quickly consolidate all information into a notebook and organize information efficiently. It can be used as a powerful tool for effective information sharing.
Information sharing
A wide range of information sharing tools are available, including chat and note sharing functions. We support information sharing with your team in all situations, from casual information sharing to organizing information in teams.
Collaboration
Provides task management functions specifically designed to make information gathering and sharing more efficient. In addition to regular task management functions, this useful tool supports information gathering and sharing, improving the productivity of the entire team.
DigitalMedical Open Innovation
BrainEnergy produce DigitalMedical open
innovation from Tokyo, where you can experience the intersection of cool and passionate design and
technology.
Transform Your Business With Cloud
Looking for the Future of Health Care
OUR TECHNOLOGY HELPS YOUR BUSINESS
Our technology will help your business
Technology
Sawai Pharmaceutical adds three new technologies to its formulation technology brand — improving print durability, evaluating the taste of OD tablets, and visualizing taste using AI.
Sawai Pharmaceutical has added three new technologies to its formulation technology brand, “SAWAI HARMOTECH®.” These include “INJIKEEP®,” which enhances the durability of printed text; “ODITEX®,” which quantitatively evaluates the texture and mouthfeel of OD tablets using equipment; and “TASTEYE®,” which visualizes the taste of medications using AI. All three are proprietary technologies that have either been patented or are currently pending patent applications.“ODITEX®” uses a tensile press and rheometer to scientifically evaluate the mouthfeel during disintegration, which was previously assessed through sensory testing or empirical rules. “TASTEYE®” combines taste sensors and AI to quantify the differences in taste between active ingredients and changes in taste due to drug interactions.While evaluations of physical properties such as tablet hardness have been conducted in the past, this is the first attempt to combine such evaluations with sensory assessments of ease of swallowing and quantify the results. Going forward, the company plans to use these technologies to map the physical properties of developed formulations to indicators of ease of swallowing and further visualize taste changes quantitatively, thereby providing patients with objective information about the ease of swallowing of medications.
Biotech Company Officially Launches Cloud Lab Service Powered by Autonomous Lab Infrastructure
PR Newswire (March 2, 2026) reported that Ginkgo Bioworks (NYSE: DNA) officially launched Ginkgo Cloud Lab, a new interface that allows researchers to transition their benchwork to Ginkgo's autonomous lab infrastructure directly through a web browser. The Cloud Lab runs on Ginkgo's proprietary Reconfigurable Automation Carts (RACs)—modular units combining high-precision robotic arms, maglev sample transport tracks, and industrial-grade software to create a flexible laboratory environment. It provides remote access to a fleet of over 70 instruments spanning critical biological unit operations including sample preparation, liquid handling, analytical readouts, storage, and incubation. The core of the initial launch is an AI-driven agent called EstiMate, which for the first time allows scientists to submit a protocol in human language and receive an immediate assessment of compatibility with Ginkgo's current autonomous fleet, along with transparent pricing for running the protocol. CEO Jason Kelly stated that autonomous labs are ready to scale and accelerate high-mix benchwork, and that opening up the autonomous infrastructure through the Cloud Lab gives scientists access to these tools today. Ginkgo Cloud Lab is part of the company's 2026 strategic shift to move all R&D services onto Nebula, its autonomous lab in Boston, MA, and decommission traditional lab benches in favor of predictable and programmable robotic infrastructure. Ginkgo is inviting researchers from academia to global biopharmaceutical companies to submit their specific protocols for development on the Cloud Lab; feasibility reports and price quotes can be requested at cloud.ginkgo.bio.
Two-step fermentation process improves smell of plant proteins
Researchers at Ohio State University developed a two-step fermentation method that removes 95–99% of off-odors from plant proteins such as soy, pea, chickpea, and hemp. The first stage uses Lactobacillus plantarum to break down odor compounds, while the second applies yogurt cultures to develop desirable aromas. The process adds no extra cost or production time, offering a practical path to more consumer-friendly plant-based foods.
Nike Says Its New Shoes Can Alter Your Mind. A Neuroscientist Weighs in.
Nike claims its new shoes can enhance sensory awareness and concentration by stimulating the feet, leveraging the rich sensory receptors in the soles. A neuroscientist, however, finds the marketing claims more dramatic than scientific reality. While foot stimulation can influence movement and awareness, and minimalist shoes can improve proprioception, there's little evidence that passive underfoot stimulation significantly boosts concentration in healthy adults. The article suggests that reported mental effects might stem from placebo effects and embodied cognition, where belief and physical states indirectly influence focus. True cognitive benefits from physical fitness are more likely derived from sustained movement, training, sleep, and attention, rather than just shoe sensation.
The Effect of Fragrance on Breathing During Sleep: New Possibilities Revealed by Large-Scale Data
Hasegawa Fragrances presented analysis results at an academic conference using 2,387 large-scale sleep data points to verify the impact of scent on breathing patterns during sleep. The experiment utilized the sleep analysis service of the capsule hotel “Nine Hours.” Using three scents—lavender, geranium, and lemongrass—and comparing them to a scent-free condition, the number of apneas per hour decreased under all scent conditions. Notably, both lavender and geranium also reduced the apnea-hypopnea index (AHI). These results suggest an influence on respiratory status during sleep. Furthermore, geranium and lemongrass also showed a tendency to reduce the number of awakenings during sleep, suggesting potential for improving sleep continuity. These findings will be presented at the Japanese Society of Sleep Research conference in June 2025, with expectations for their application in aroma-based sleep care and fragrance product development.
It should be noted that the sleep metric values are reference values provided by Nine Hours Inc. and are not measurements obtained from medical devices.
Advancing drug discovery with reproducible, animal-free 3D systems
Lukas Gaats and his team at mo:re are leveraging automation to enhance reproducibility in 3D cell culture and advance animal-free drug discovery. The company develops 3D models derived from human cells, demonstrating superior accuracy in predicting drug safety and efficacy, particularly for liver and kidney toxicity, compared to animal models. This approach also addresses ethical concerns and aligns with regulatory shifts towards non-animal methods. Their flagship system, "MO:BOT," is the first fully automated 3D cell-culture platform, ensuring biological integrity, high standardization, and reproducibility through automated processes from cell seeding to medium exchange, including in-process quality control. This technology facilitates the rapid generation of reliable preclinical data, potentially accelerating regulatory approvals and reducing drug development costs by enabling more efficient testing with smaller sample sizes. Automated New Approach Methodologies (NAMs) are considered crucial for the future of personalized medicine and are expected to significantly reduce animal testing over the next decade.
Verana Health Enhances Site Explorer Tool to Expedite Urology Clinical Trials
Verana Health®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD), has launched updates to its Site Explorer application. Site Explorer now includes exclusive data from urology practices in addition to ophthalmology practices, expanding researchers ability to quickly find the study sites and model protocols, reduce recruitment timelines, and build enrollment cohorts reflective of subpopulation demographics.
The Creation of the First AI-Generated Control Cabinet
At SPS 2025, WSCAD and its partners unveiled the world's first AI-generated control cabinet, heralding a new era in electrical planning by automating traditional processes and significantly reducing design time. The AI integrates and automates complex stages such as planning, layout, wiring, labeling, and manufacturing data generation based on digital circuit diagrams, creating a digital twin. This enhances data consistency and reduces human errors. Material lists and wiring information are also automatically generated, and the effort for creating multilingual documents is reduced. However, AI does not assume technical responsibility and its quality depends on the input data, making the electrical designer's expertise and final approval indispensable. AI serves as a support tool, with its true potential lying in the combination of automated assistance and human engineering expertise.
Xcell Biosciences and Culture Biosciences Partner to Advance Cell Therapy Quality Through AI and Machine Learning
Xcell Biosciences and Culture Biosciences announced a partnership to enhance data analysis and access for cell therapies under development or manufacture in Xcellbio's AVATAR™ Foundry system. This collaboration integrates Culture's AI and machine learning tools, enabling scientists to remotely monitor cell incubation data, including temperature, oxygen, and pH levels, and conduct detailed analyses. This is expected to optimize cell therapy development and manufacturing processes, leading to improved patient outcomes.
M2 Ingredients to unveil new functional mushroom innovation lab
M2 Ingredients, a California-based functional mushroom grower, is set to open its new 'M2 Center of Innovation' next month to accelerate functional mushroom product development. This R&D lab will support the creation of functional foods, beverages, and supplements across various formats, addressing challenges like solubility, suspension, and flavor pairing. Fully integrated with their existing cultivation facility, the center will formally open on February 2, 2026, aiming to foster faster product innovation through collaboration with brand partners.
Swiss wearable glucose-monitoring technology startup Liom closes €13.9 million round
Schwyz-based Liom, an innovator in non-invasive biomarker monitoring and the developer of a non-invasive glucose-monitoring wearable, announced a €13.9 million (CHF 13 million) extension of its Series A financing round.
The round was led by previous lead investors, with new participation from Red Bull Ventures, Marc Maurer (former co-CEO of On Running), Melih Odemis (former co-founder and CTO of Yemeksepeti), Alejo Costa Ribalta, partner of venture capital firm CRB Health Tech and former senior executive of Philips and GE Healthcare – bringing its total Series A to €40.8 million (CHF 38 million) and its total funding to date to €67.6 million (CHF 63 million).
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
Equity Insider News Commentary – Traditional pharmaceutical strategies are giving ground as breakthrough approvals for gene therapies and mRNA platforms target previously untreatable rare diseases with precision interventions[1]. Healthcare systems integrating AI diagnostic tools now match therapies to individual genetic profiles rather than treating broad populations with reactive symptom management[2]. Five companies positioned at this convergence include Avant Technologies, Inc. (OTCQB: AVAI), Beam Therapeutics Inc. (NASDAQ: BEAM), CRISPR Therapeutics (NASDAQ: CRSP), Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), and Schrödinger, Inc. (NASDAQ: SDGR).
BlueNalu Announces Insider-Led Convertible Note and Preferred Stock Financings to Advance Commercialization of Cell-Cultivated Bluefin Tuna Toro
BlueNalu, a global leader in the development of cell-cultivated seafood, today announced new convertible note and preferred stock financings. The financings were led by Agronomics, Siddhi Capital, and Lewis & Clark AgriFood, with additional participation from approximately 40 other existing investors. In the financings, BlueNalu secured approximately $11 million in cash and stock proceeds.
Participation to date reflects the continued commitment of BlueNalu’s global investor base and reinforces the company’s leadership position as it advances toward the commercialization of premium, high-value seafood products produced directly from fish cells.